We are thrilled to share that Passage Bio has received positive feedback from the FDA on expanding our upliFT-D trial of PBFT02 to include patients with frontotemporal dementia (#FTD) due to C9orf72 gene mutations. This expansion is a significant milestone in our mission to improve the lives of patients with neurodegenerative diseases. Read more here: https://lnkd.in/eQpgQsVD
Passage Bio
Biotechnology Research
Philadelphia, Pennsylvania 14,190 followers
World-class genetic medicines company that’s changing the future of CNS disease
About us
We are a genetics medicine company based in Philadelphia, PA, a city with a rich history of scientific discovery and medical advancement. As a leading developer of cutting-edge therapeutics for disorders of the central nervous system (CNS), we are proud to be a part of this dynamic research community. We are also excited about our new laboratory at the Princeton West Innovation Campus in Hopewell, New Jersey, which will help us evolve the standard for biotech innovation and development. At Passage Bio, we have a bold vision to fulfill the promise of gene therapy and a differentiated approach to gene therapy development through our collaboration with University of Pennsylvania's Gene Therapy Program and Orphan Disease Center. Our deep pipeline of optimized gene therapies for CNS disorders includes lead programs focused on the following devastating diseases: GM1 gangliosidosis Krabbe disease Frontotemporal dementia
- Website
-
http://www.passagebio.com/home/default.aspx
External link for Passage Bio
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Philadelphia, Pennsylvania
- Type
- Public Company
- Founded
- 2017
Locations
-
Primary
2005 Market Street
39th Floor
Philadelphia, Pennsylvania 19103, US
Employees at Passage Bio
Updates
-
We are pleased to announce the out-licensing of our pediatric lysosomal storage disease programs to Gemma Biotherapeutics, a new company founded by James M. Wilson, M.D., Ph.D., that is committed to advancing promising gene therapies for children with #GM1, #Krabbe, and #MLD. This strategic move extends our cash runway, enabling us to continue our vital work in adult neurodegenerative diseases. Additionally, Passage Bio will launch a new research partnership with Gemma Biotherapeutics that will leverage our combined expertise to explore new frontiers in CNS research. Read more here: https://loom.ly/EC6p40I
-
Did you know that Progranulin (PGRN) could unlock breakthroughs in the treatment of neurodegenerative diseases? At Passage Bio, we are exploring the therapeutic potential of elevating PGRN levels in the central nervous system to alter the course of neurodegenerative diseases. Discover more here: https://loom.ly/GtdTEMQ
Passage Bio, Inc. - Our Science - Role of Progranulin
passagebio.com
-
If you or a loved one has #FTD, genetic counseling and testing are essential. It can pinpoint if a mutation caused your FTD, provide insights into your symptoms, and identify clinical trial eligibility, such as the upliFT-D trial for FTD-GRN. InformedDNA offers free genetic testing and counseling for US residents. Learn more here: https://loom.ly/hm5g0lc
Passage BIO FTD
https://informeddna.com
-
It was an honor to have BiotechTV come visit our Philadelphia headquarters and discuss exciting milestones on the horizon for Passage!
𝐁𝐞𝐡𝐢𝐧𝐝 𝐭𝐡𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞: Philadelphia-based Passage Bio is aiming to treat frontotemporal dementia by using an AAV gene therapy to boost progranulin levels in the brain. CEO Will Chou describes the scientific rationale for elevating progranulin, what the company has seen in the first three patients treated, and previews an upcoming conference in September. Full video: https://lnkd.in/g5zWV7id BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
Check out our recent podcast appearance! Our CEO Will Chou, MD, recently joined the Life Science Success Podcast to share updates from our ongoing clinical study for #FTD, the urgency of developing treatments for genetic mutations, and the potential impact on patients and their families. Tune in for insights here: https://loom.ly/XCh2t9E #LifeScienceSuccess
Dr. William Chou on Gene Therapy for Neurodegenerative Diseases
lifesciencesuccess.com
-
As Alzheimer's & Brain Awareness Month comes to a close, we reflect on our ongoing commitment to advance gene therapies that have the potential to change the lives of patients and their families with neurodegenerative conditions. We are proud to continue our work advancing research and developing treatments that address the urgent needs of the neurodegenerative disease community. Learn more about our ongoing efforts here: https://loom.ly/WkGeVEQ #ENDALZ
Clinical Trial Pipeline | Passage Bio
passagebio.com
-
Last week, our Passage Bio team had an unforgettable summer team-building event at Grounds for Sculpture. This museum, sculpture garden, and arboretum offered the perfect blend of art and nature, with nearly 300 contemporary sculptures across 42 landscaped acres and six galleries showcasing amazing exhibitions. With colleagues spread across different locations, we truly value the time we can spend together!
-
-
Passage Bio recognizes #Juneteenth, the oldest nationally celebrated commemoration of the ending of slavery in the United States. We are proud to give our employees the day off to reflect, educate themselves, and engage in meaningful conversations about race and justice. Explore a curated Juneteenth reading list with resources that highlight the significance of this day here: https://loom.ly/2IuxQcA
Juneteenth Reading List
nmaahc.si.edu